LifeScan pairs latest blood glucose meter to FDA-approved diabetes management app

WAYNE, Pa. - LifeScan, a business within the Johnson & Johnson Diabetes Care Companies, on Tuesday announced a strategic collaboration through its affiliate Cilag with WellDoc Corporation to integrate LifeScan's newly launched OneTouch Verio Flex blood glucose monitoring system with WellDoc's BlueStar diabetes management platform and mobile application. 

 

"We are continuously working to empower diabetes patients by developing and integrating innovative technologies that can improve both daily experiences and long-term health," stated Val Asbury, Worldwide President, LifeScan. "This exciting collaboration bridges our strong history serving diabetes patients and their healthcare team with WellDoc's innovative diabetes management platform that has been shown to improve health outcomes. By working together, we look forward to advancing new solutions."

 

LifeScan's new OneTouch features both built-in Bluetooth Smart Technology and ColorSure technology – making for a simple, accurate and easy-to-use meter that takes the guesswork out of understanding blood sugar test results for people with diabetes. And WellDoc's BlueStar diabetes management platform and mobile application is the first mobile prescription therapy approved by the U.S. Food and Drug Administration for Type 2 diabetes.  

 

The integration would provide patients additional smart monitoring tools and real-time motivational, behavioral and educational coaching, which clinical studies have shown improve patient health.

 

Johnson & Johnson Innovation had participated with other investors in WellDoc's Series B financing. This new relationship exemplifies Johnson & Johnson's cross-sector strategy of collaborating with a wide range of technology companies to create new ways that help people live longer, healthier lives.